CYTOKINETICS, INCORPORATED Increase (Decrease) in Contract with Customer, Asset
CYTOKINETICS, INCORPORATED (CYTK) reported Increase (Decrease) in Contract with Customer, Asset of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2022-02-25
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for the quarter ending 2020-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for the quarter ending 2020-09-30 was $0.00.
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for the quarter ending 2020-06-30 was $0.00.
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for the quarter ending 2020-03-31 was $0.00.
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for fiscal 2021 was $0.00.
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for fiscal 2020 was $0.00.
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for fiscal 2019 was -$4.55M.
- CYTOKINETICS, INCORPORATED increase (decrease) in contract with customer, asset for fiscal 2018 was -$5.15M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-25 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $0.00 derived: sum of 3 quarters · filed 2022-02-25 | $0.00 10-K · filed 2022-02-25 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $0.00 10-Q · filed 2020-08-07 | $0.00 derived: sum of 3 quarters · filed 2022-02-25 | -$575.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | -$575.00K derived: sum of 3 quarters · filed 2022-02-25 | -$2.47M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$575.00K derived: sum of 2 quarters · filed 2022-02-25 | -$2.47M derived: sum of 3 quarters · filed 2022-02-25 | -$4.55M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$575.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$2.47M derived: sum of 2 quarters · filed 2020-11-06 | -$4.55M 10-Q · filed 2020-11-06 | $3.83M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$3.98M 10-Q · filed 2020-08-07 | $4.40M derived: sum of 3 quarters · filed 2021-02-26 | -$95.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$2.08M 10-Q · filed 2020-05-08 | $6.30M derived: sum of 2 quarters · filed 2021-02-26 | $1.80M derived: sum of 3 quarters · filed 2021-02-26 | -$4.02M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $3.88M derived: sum of 2 quarters · filed 2021-02-26 | -$1.94M derived: sum of 3 quarters · filed 2021-02-26 | -$5.15M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | -$10.32M derived: sum of 2 quarters · filed 2019-11-01 | -$13.54M 10-Q · filed 2019-11-01 | -$13.54M derived: sum of 4 quarters · filed 2019-11-01 |
| 2018-06-30 | -$5.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$9.04M 10-Q · filed 2019-08-09 | -$9.04M derived: sum of 3 quarters · filed 2019-08-09 | -$9.04M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | -$3.21M 10-Q · filed 2019-05-09 | -$3.21M derived: sum of 2 quarters · filed 2019-05-09 | -$3.21M derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 10-K · filed 2019-03-07 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |